Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Aug 2021
Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
30 July 2021 - Benlysta (belimumab) has been approved in Canada for the treatment of active lupus nephritis in adult ...
Posted by Michael Wonder on 02 Aug 2021
Six month countdown to go live for the Clinical Trials Information System
2 August 2021 - The European Commission has confirmed that the entry into application of the Clinical Trials Regulation and ...
Posted by Michael Wonder on 02 Aug 2021
Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
2 August 2021 - Saphnelo is a first in class type I interferon receptor antibody and the only new medicine ...
Posted by Michael Wonder on 02 Aug 2021
ATAGI statement regarding vaccination of adolescents aged 12–15 years
2 August 2021 - Following the recent approval by the TGA for the provisional registration of the Comirnaty (Pfizer) COVID-19 vaccine ...
Posted by Michael Wonder on 02 Aug 2021
Government subsidises medicine to combat high cholesterol in ‘high-risk’ Australians
1 August 2021 - Experts are welcoming the PBS listing of a medicine that helps reduce unacceptably high ‘bad cholesterol’ ...
Posted by Michael Wonder on 02 Aug 2021
Uptravi (selexipag) receives FDA approval for intravenous use in adult patients with pulmonary arterial hypertension
30 July 2021 - New formulation allows for uninterrupted treatment for pulmonary arterial hypertension patients temporarily unable to take oral therapy. ...
Posted by Michael Wonder on 02 Aug 2021
National Medicines Policy Review will be significant for all Australians
30 July 2021 - Medicines Australia is eager to be part of a significant moment in history for Australian health ...
Posted by Michael Wonder on 02 Aug 2021
Reducing the cost of medicines through new PBS listings
1 August 2021 - From August 1, the Australian Government is listing a number of new medicines on the PBS to ...
Posted by Michael Wonder on 01 Aug 2021
FDA under pressure to grant full approval to COVID-19 vaccines
1 August 2021 - Some schools, hospitals and employers are hesitant to mandate vaccines while shots are still only authorized for ...
Posted by Michael Wonder on 01 Aug 2021
Muscular atrophy, cholesterol and migraine medications added to PBS
1 August 2021 - Australians living with chronic health conditions will save up to $123,000 per year with the addition ...
Posted by Michael Wonder on 01 Aug 2021
Family says choice is life in Australia or death waiting for PHARMAC
2 August 2021 - A Tauranga couple is splitting up their family so their daughter can access treatment for spinal muscular ...
Posted by Michael Wonder on 31 Jul 2021
FDA authorises REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis for COVID-19
30 July 2021 - The U.S. FDA today revised the emergency use authorisation for REGEN-COV (casirivimab and imdevimab, administered together) authorising ...
Posted by Michael Wonder on 31 Jul 2021
FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
29 July 2021 - In a long-awaited move, the FDA has approved the first so-called interchangeable biosimilar version of insulin, ...
Posted by Michael Wonder on 31 Jul 2021
New migraine, spinal muscular atrophy drugs on PBS ease financial pain
1 August 2021 - New drugs for spinal muscular atrophy, migraine and high cholesterol are being added to the pharmaceutical ...
Posted by Michael Wonder on 31 Jul 2021
Schedule of Pharmaceutical Benefits - 1 August 2021
1 August 2021 - The August 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...